Traders assign a 91% probability to no new COVID-19 variant of concern before 2027 because SARS-CoV-2 circulation remains at multi-year lows globally, with test positivity near 1-2% and no lineages demonstrating the transmissibility, severity, or immune-evasion traits that historically trigger WHO VOC designations. Current variants under monitoring—such as XFG, NB.1.8.1, and BA.3.2—show stable or declining shares in genomic surveillance, without evidence of rapid displacement or heightened public-health impact. Updated 2026-2027 vaccines targeting XFG reflect routine adaptation rather than crisis-level change. With only four months remaining and surveillance data through mid-2026 showing no acceleration, the market reflects broad consensus that a qualifying new variant is unlikely to emerge and be classified in time.